BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35325818)

  • 1. Generation of the induced pluripotent stem cell line UKWNLi005-A derived from a patient with the GLA mutation c.376A > G of unknown pathogenicity in Fabry disease.
    Breyer M; Klein T; Klug K; Klopocki E; Üçeyler N
    Stem Cell Res; 2022 May; 61():102747. PubMed ID: 35325818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of the human induced pluripotent stem cell line (UKWNLi001-A) from skin fibroblasts of a woman with Fabry disease carrying the X-chromosomal heterozygous c.708 G > C (W236C) missense mutation in exon 5 of the alpha-galactosidase-A gene.
    Klein T; Günther K; Kwok CK; Edenhofer F; Üçeyler N
    Stem Cell Res; 2018 Aug; 31():222-226. PubMed ID: 30130681
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Breyer M; Grüner J; Klein A; Finke L; Klug K; Sauer M; Üçeyler N
    Mol Genet Metab Rep; 2024 Mar; 38():101029. PubMed ID: 38469097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation and characterization of iPS cell line (CTGUi001-A) from skin fibroblasts of a patient with Fabry disease.
    Qin Y; Zhan JQ; Ma CJ; Cao CY; Zhang Y; Min YT; Lv YF
    Stem Cell Res; 2023 Jun; 69():103063. PubMed ID: 36917862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of a CRISPR/Cas9-corrected-hiPSC line (DDLABi001-A) from Fabry disease (FD)-derived iPSCs having α-galactosidase (GLA) gene mutation (c.803_806del).
    Choi JB; Seo D; Do HS; Han YM
    Stem Cell Res; 2023 Feb; 66():103001. PubMed ID: 36516658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of a GLA knock-out human-induced pluripotent stem cell line, KSBCi002-A-1, using CRISPR/Cas9.
    Kim YK; Yu JH; Min SH; Park SW
    Stem Cell Res; 2020 Jan; 42():101676. PubMed ID: 31841972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human-induced pluripotent stem cell lines (CMCi006-A and CMCi007-A) from a female and male patient with Fabry disease carrying the same frameshift deletion mutation.
    Cui S; Shin YJ; Ko EJ; Lim SW; Ju JH; Lee KI; Lee JY; Yang CW; Chung BH
    Stem Cell Res; 2021 Mar; 51():102214. PubMed ID: 33545641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of induced pluripotent stem cell line (UKWNLi008) derived from a patient carrying a c.1678C>G variant in the transient receptor potential cation channel subfamily A member (TRPA1) gene potentially associated with small fiber neuropathy.
    Schottmann NM; Klug K; Klopocki E; Üçeyler N
    Stem Cell Res; 2023 Jun; 69():103094. PubMed ID: 37079968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of an induced pluripotent stem cell line (ZJUi007-A) from a 11-year-old patient of Fabry disease.
    Zhu Y; Zhang L; Wang G; Zhao J; Hou X; Wu H; Xu Y; Mao J; Liu Z; Zhang J
    Stem Cell Res; 2021 Aug; 55():102475. PubMed ID: 34365103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Energy utilization of induced pluripotent stem cell-derived cardiomyocyte in Fabry disease.
    Chou SJ; Yu WC; Chang YL; Chen WY; Chang WC; Chien Y; Yen JC; Liu YY; Chen SJ; Wang CY; Chen YH; Niu DM; Lin SJ; Chen JW; Chiou SH; Leu HB
    Int J Cardiol; 2017 Apr; 232():255-263. PubMed ID: 28082092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation.
    Chien Y; Chien CS; Chiang HC; Huang WL; Chou SJ; Chang WC; Chang YL; Leu HB; Chen KH; Wang KL; Lai YH; Liu YY; Lu KH; Li HY; Sung YJ; Jong YJ; Chen YJ; Chen CH; Yu WC
    Oncotarget; 2016 Dec; 7(52):87161-87179. PubMed ID: 27888626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of the Inflammatory Responses in Fabry Patient iPSC-Derived Cardiovascular Endothelial Cells by CRISPR/Cas9-Corrected Mutation.
    Song HY; Yang YP; Chien Y; Lai WY; Lin YY; Chou SJ; Wang ML; Wang CY; Leu HB; Yu WC; Chien CS
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A late-onset male Fabry disease patient with somatic mosaicism of a classical GLA mutation: a case report.
    Bae EH; Choi JM; Ki CS; Ma SK; Yoo HW; Kim SW
    Ann Palliat Med; 2021 Apr; 10(4):4926-4931. PubMed ID: 33040545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of human induced pluripotent stem cell line MHHi029-A from a male Fabry disease patient carrying c.959A > T mutation.
    Jahn C; Juchem M; Sonnenschein K; Gietz A; Buchegger T; Lachmann N; Göhring G; Behrens YL; Bär C; Thum T; Hoepfner J
    Stem Cell Res; 2024 Mar; 77():103404. PubMed ID: 38552356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene variants of unknown significance in Fabry disease: Clinical characteristics of c.376A>G (p.Ser126Gly).
    Lau K; Üçeyler N; Cairns T; Lorenz L; Sommer C; Schindehütte M; Amann K; Wanner C; Nordbeck P
    Mol Genet Genomic Med; 2022 May; 10(5):e1912. PubMed ID: 35212486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individuals.
    Ter Huurne M; Parker BL; Liu NQ; Qian EL; Vivien C; Karavendzas K; Mills RJ; Saville JT; Abu-Bonsrah D; Wise AF; Hudson JE; Talbot AS; Finn PF; Martini PGV; Fuller M; Ricardo SD; Watt KI; Nicholls KM; Porrello ER; Elliott DA
    Am J Hum Genet; 2023 Sep; 110(9):1600-1605. PubMed ID: 37607539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of the human induced pluripotent stem cell line UKWNLi002-A from dermal fibroblasts of a woman with a heterozygous c.608 C>T (p.Thr203Met) mutation in exon 3 of the nerve growth factor gene potentially associated with hereditary sensory and autonomic neuropathy type 5.
    Klein T; Henkel L; Klug K; Kwok CK; Klopocki E; Üçeyler N
    Stem Cell Res; 2018 Dec; 33():171-174. PubMed ID: 30384131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling of Fabry disease nephropathy using patient derived human induced pluripotent stem cells and kidney organoid system.
    Cui S; Fang X; Lee H; Shin YJ; Koh ES; Chung S; Park HS; Lim SW; Lee KI; Lee JY; Yang CW; Chung BH
    J Transl Med; 2023 Feb; 21(1):138. PubMed ID: 36814269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variants of unknown significance in alpha-galactosidase A: Cellular delineation from Fabry disease.
    Klein A; Klug K; Breyer M; Grüner J; Medala VK; Nordbeck P; Wanner C; Klopocki E; Üçeyler N
    J Inherit Metab Dis; 2024 Apr; ():. PubMed ID: 38618884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of Fabry cardiomyopathy model for drug screening using induced pluripotent stem cell-derived cardiomyocytes from a female Fabry patient.
    Kuramoto Y; Naito AT; Tojo H; Sakai T; Ito M; Shibamoto M; Nakagawa A; Higo T; Okada K; Yamaguchi T; Lee JK; Miyagawa S; Sawa Y; Sakata Y; Komuro I
    J Mol Cell Cardiol; 2018 Aug; 121():256-265. PubMed ID: 30048710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.